Chronic Fatigue Syndrome therapeutics market size will grow by USD 51.84 million, increasing the use of unapproved pharmacological treatment for Chronic Fatigue Syndrome to drive market growth

NEW YORK, August 3, 2022 /PRNewswire/ — The “Chronic Fatigue Syndrome Therapeutic Market by product (analgesics and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs) and geography (North America, Europe, Asiaand Rest of World (ROW)) – Forecast and Analysis 2022-2026″ was added to Technavio’s offering. The potential growth difference for Chronic Fatigue Syndrome Therapies market size between 2021 and 2026 is $51.84 million. To get the exact CAGR and year over year growth rate, Request a sample report

Technavio has announced its latest market research report titled Chronic Fatigue Syndrome Therapeutics Market By Product & Geography : Forecast & Analysis 2022-2026

Technavio has announced its latest market research report titled Chronic Fatigue Syndrome Therapeutics Market By Product & Geography : Forecast & Analysis 2022-2026

Key Market Dynamics:

  • Market Driver: The increasing use of unapproved pharmacological treatments for CFS is driving the growth of the market. Graded exercise and CBT are considered the first-line treatment for CFS. CFS patients are more likely to see a complementary or alternative healthcare provider rather than a physical therapist or psychologist for advice and support. As there are no approved medications for the treatment of chronic fatigue syndrome, a wide variety of pain relievers, antidepressants, antibiotics, and immunomodulators are prescribed to improve symptoms.

  • Market challenge: the confirmation of specific diagnostic tests for confirmation of CFS is challenging market growth. CFS can be a symptom of other medical conditions, such as chronic mononucleosis, fibromyalgia, neurological conditions, Lyme disease, and sensitivity to certain chemicals. It can also be a symptom of many treatable illnesses, including depression, cancer, subacute or chronic infections, psychosomatic illnesses, and malingering. Therefore, more education about CFS among health professionals is required. Such factors may challenge the growth of the market in the forecast years.

Technavio provides drivers, trends and challenges that will affect the future of the market. View a sample report

Market segmentation

North America it will be the leading region with 42% of the market growth during the forecast period. The growth is attributed to factors such as high pharmaceutical spending per capita, access to advanced healthcare, the strong market presence of leading providers, and growing awareness of chronic fatigue syndrome. Also, the market growth in this region will be faster than the market growth in other regions. The US and Canada are the key countries for the chronic fatigue syndrome therapeutic market in North America. The increasing prevalence of CFS in the US is also driving regional market growth. According to the Centers for Disease Control (CDC), the prevalence of CFS in the US is around 11.5%.

the pain relievers and NSAIDs segment will have significant market share growth during the forecast period. Pain relievers are the most commonly used medications as they can help relieve pain and reduce inflammation. Ibuprofen is the most widely used NSAID. Body pain is the most common reason for NSAID use in patients with CFS. Arthritis and headache are the second and third most frequently reported reasons, respectively.

Learn about the contribution of each segment summarized in concise infographics and detailed descriptions. View a sample report

Some companies mentioned

  • AIM ImmunoTech Inc.

  • apotex inc.

  • Aurobindo Pharma Ltd.

  • Bionfarma Inc.

  • Cadila Pharmaceuticals Ltd.

  • hikma pharmaceuticals plc

  • lupine ltd.

  • pfizer inc.

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

  • viatris inc.

Do you want your personalized report? Talk to an analyst and customize your report according to your needs.

Related reports

Drug market for narcolepsy by Type and Geography – Forecast and Analysis 2022-2026

Mental Health Marketplace by Service and Geography – Forecast and Analysis 2022-2026

Chronic Fatigue Syndrome Therapeutics Market Scope

Report Coverage


Page number


base year


forecast period


Growth momentum and CAGR

Accelerates to a CAGR of 4.31%

Market growth 2022-2026

$51.84 million

market structure


YoY growth (%)


regional analysis

North America, Europe, Asia and Rest of the World (ROW)

Contribution to the real market

North America at 42%

Main consumer countries

US, Canada, Germany, UK, France, US, Canada, Germany, UK, France

competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

AIM ImmunoTech Inc., Apotex Inc., Aurobindo Pharma Ltd., Bionpharma Inc., Cadila Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Lupin Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and Viatris Inc. .

market dynamics

Major market analysis, market growth drivers and obstacles, fast and slow growing segments analysis, impact of COVID-19 and future consumer dynamics, and market condition analysis for the forecast period.

Customization Scope

If our report didn’t include the data you’re looking for, you can contact our analysts and get custom segments.

Browse Health care Market research reports

Key Topics Covered:

1. Executive Summary

2 Market Landscape

3 Market size

4 Five Forces Analysis

5 Market segmentation by product

6 Customer landscape

7 Geographic Landscape

8 drivers, challenges and trends

9 Provider Landscape

10 Supplier Analysis

11 Appendix

About us

Technavio is a world leader in technology research and consulting. His research and analysis focus on emerging market trends and provide actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialist analysts, Technavio’s reporting library consists of more than 17,000 reports and counting, spanning 800 technologies and spanning 50 countries. Its client base consists of companies of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market insights to identify opportunities in existing markets and and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Mayda
Media and Marketing Executive
USA: +1 844 364 1100
United Kingdom: +44 203 893 3200

Technavio (PRNewsfoto/Technavio)

Technavio (PRNewsfoto/Technavio)



View original content to download media: drug-treatment-for-cfs-to-drive-market-growth—technavio-301597588.html

SOURCE Technavio

Leave a Reply

Your email address will not be published.